Why the study?
The study aimed to develop a dual drug-delivery nanocarrier for sirolimus and heparin to inhibit restenosis after balloon angioplasty.
Does combinatorial delivery of sirolimus and heparin via PgP nanoparticles reduce restenosis in injured porcine coronary arteries ex vivo?
Does combinatorial delivery of sirolimus and heparin via PgP nanoparticles reduce restenosis in injured porcine coronary arteries ex vivo?
Answers are grounded in this paper and cite their sources.
A novel nanoparticle carrier for dual delivery of sirolimus and heparin effectively inhibits restenosis markers in an ex vivo porcine model of balloon angioplasty.
Aim: To develop poly(lactide-co-glycolide)-graft-polyethylenimine (PgP) as a dual drug-delivery carrier for sirolimus (SR) and heparin (Hep) to inhibit restenosis after balloon angioplasty. Materials & methods: SR was loaded in the hydrophobic core and negatively charged Hep complexed with the positively charged hydrophilic shell of PgP. SR- and Hep-loaded PgP was tested on rat aortic smooth muscle cells in vitro and injured porcine coronary arteries after balloon angioplasty ex vivo. Results & conclusion: SR and Hep loading efficiency in PgP were approximately 37 and 82%, respectively. SR- and Hep-loaded PgP treatment decreased smooth muscle cell proliferation up to 14 days post-treatment and decreased proliferation, collagen deposition and neointimal thickness and increased patency in porcine coronary arteries after balloon angioplasty ex vivo.
No takes yet. Share an insight, caveat, or question.
Betala et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: